Reprogramming immune cells to fight recurrent brain cancer
STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBM
This study is testing a new treatment for people with recurrent glioblastoma by using a special compound to help boost the immune system's ability to fight the cancer, and researchers will closely watch how well it works.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10898592 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma (GBM), a type of aggressive brain cancer, and aims to reprogram specific immune cells known as tumor-associated myeloid cells to enhance their ability to attack tumors. The study utilizes a novel compound called IACS-8803, which activates the STING pathway, a critical immune response mechanism. Patients with recurrent GBM will receive this treatment, and the effects on their immune response and tumor characteristics will be closely monitored using advanced imaging techniques. The goal is to determine how effectively this approach can stimulate the immune system to combat the cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with recurrent glioblastoma who are eligible for surgical resection.
Not a fit: Patients with non-recurrent glioblastoma or those who are not surgical candidates may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment strategy that enhances the immune system's ability to fight recurrent glioblastoma.
How similar studies have performed: Previous studies have shown promising results with similar immune-modulating approaches in treating glioblastoma, indicating potential for success in this novel application.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Heimberger, Amy Beth — Northwestern University at Chicago
- Study coordinator: Heimberger, Amy Beth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.